Response of Rat Thoracic Aorta to F2-Isoprostane Metabolites
暂无分享,去创建一个
P. Devillier | J. Cracowski | G. Bessard | F. Stanke-Labesque | T. Durand | A. Guy | J. Rossi | G. Hardy | Laetitia Camus
[1] P. Devillier,et al. Vascular Biology of the Isoprostanes , 2001, Journal of Vascular Research.
[2] T. Durand,et al. Total Syntheses of Four Metabolites of 15‐F2t‐Isoprostane , 2001 .
[3] G. FitzGerald,et al. Cardiovascular Responses to the Isoprostanes iPF2α-III and iPE2-III Are Mediated via the Thromboxane A2 Receptor In Vivo , 2000 .
[4] T. Durand,et al. Total synthesis of 4(RS)-F4t-isoprostane methyl ester , 2000 .
[5] J. Morrow,et al. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. , 2000, Free radical biology & medicine.
[6] G. FitzGerald,et al. Specific Analysis in Plasma and Urine of 2,3-Dinor-5,6-dihydro-isoprostane F2α-III, a Metabolite of Isoprostane F2α-III and an Oxidation Product of γ-Linolenic Acid* , 2000, The Journal of Biological Chemistry.
[7] L. Lerman,et al. Enhanced coronary vasoconstriction to oxidative stress product, 8-epi-prostaglandinF2 alpha, in experimental hypercholesterolemia. , 1999, Cardiovascular research.
[8] R. Fanelli,et al. Identification and Measurement of Endogenous β-Oxidation Metabolites of 8-epi-Prostaglandin F2α* , 1999, The Journal of Biological Chemistry.
[9] T. Montine,et al. Formation of Isoprostane-like Compounds (Neuroprostanes) in Vivo from Docosahexaenoic Acid* , 1998, The Journal of Biological Chemistry.
[10] S. Basu,et al. Metabolism of 8‐iso‐prostaglandin F2α , 1998 .
[11] G. FitzGerald,et al. Nomenclature of isoprostanes: a proposal. , 1997, Prostaglandins.
[12] E. Anggard,et al. Evidence for the formation of F3-isoprostanes during peroxidation of eicosapentaenoic acid. , 1997, Biochemical and biophysical research communications.
[13] T. Evans,et al. Evidence for a dilator function of 8‐iso prostaglandin F2α in rat pulmonary artery , 1997 .
[14] J. Morrow,et al. A nomenclature system for the isoprostanes. , 1997, Prostaglandins.
[15] H. Schild,et al. SOME QUANTITATIVE USES OF DRUG ANTAGONISTS , 1997, British journal of pharmacology and chemotherapy.
[16] B. Kromer,et al. Coronary artery constriction by the isoprostane 8‐epi prostaglandin F2α , 1996, British journal of pharmacology.
[17] J. Morrow,et al. Identification of the Major Urinary Metabolite of the F2-isoprostane 8-Iso-prostaglandin F2α in Humans* , 1996, The Journal of Biological Chemistry.
[18] E. Hellström‐Lindahl,et al. Cloning of the rat and human prostaglandin F2α receptors and the expression of the rat prostaglandin F2α receptor , 1994 .
[19] Y. Boie,et al. Cloning and expression of a cDNA for the human prostanoid IP receptor. , 1994, The Journal of biological chemistry.
[20] J. Morrow,et al. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[21] B. P. White,et al. GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro , 1989, British journal of pharmacology.
[22] R. A. Coleman,et al. COMPARISON OF THE ACTIONS OF U‐46619, A PROSTAGLANDIN H2‐ANALOGUE, WITH THOSE OF PROSTAGLANDIN H2 AND THROMBOXANE A2 ON SOME ISOLATED SMOOTH MUSCLE PREPARATIONS , 1981, British journal of pharmacology.
[23] P. Devillier,et al. Cysteinyl leukotrienes are involved in angiotensin II-induced contraction of aorta from spontaneously hypertensive rats. , 2001, Cardiovascular research.
[24] G. FitzGerald,et al. Specific analysis in plasma and urine of 2,3-dinor-5, 6-dihydro-isoprostane F(2alpha)-III, a metabolite of isoprostane F(2alpha)-III and an oxidation product of gamma-linolenic acid. , 2000, The Journal of biological chemistry.
[25] Y. Boie,et al. Cloning and expression of a cDNA for the human prostanoid FP receptor. , 1994, The Journal of biological chemistry.
[26] E. Hornby,et al. Pathophysiological actions of thromboxane A2 and their pharmacological antagonism by thromboxane receptor blockade with GR32191. , 1990, Circulation.